Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HB134
- Development stage
- Preclinical
- Lead developer
- Huahui Health
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HB134 is a bispecific T-cell engager (TCE) targeting leukocyte immunoglobulin-like receptor B4 (LILRB4) and CD3, developed by Huahui Health for the treatment of monocytic acute myeloid leukemia (AML). The molecule is engineered by fusing an anti-LILRB4 nanobody and an anti-CD3 Fab to a human IgG1 scaffold with a silent Fc region. LILRB4 is a specific marker overexpressed in monocytic AML subtypes (M4 and M5) but absent in normal hematopoietic stem cells, providing a therapeutic window. HB134 works by recruiting T cells to LILRB4-positive leukemia cells, inducing potent T-cell activation and tumor cell cytotoxicity while maintaining a favorable safety profile with low induction of proinflammatory cytokines in preclinical studies.
02
Targets
CD3 (T-cell surface glycoprotein CD3)LILRB4
Beyond the preview
Go deeper on HB134.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HB134.